The Russian FSHD registry: a first look at the cohort
Anna KuchinaiD, Darya SherstyukovaiD, Artem O. BorovikoviD, Margarita А. SoloshenkoiD, Nikolay V. ZernoviD, Dmitrii SubbotiniD, Дадали Елена ЛеонидовнаiD, Шаркова Инна ВалентиновнаiD, Galina E. RudenskayaiD, Sergey Ivanovich KutseviD, Mikhail Y. SkobloviD, Aysylu F. MurtazinaiD
Abstract
BackgroundFacioscapulohumeral muscular dystrophy (FSHD) is a common hereditary neuromuscular disorder. The Russian FSHD Patient Registry was established in 2019 following the development of a PCR-based method for genetic confirmation of the diagnosis. ResultsThe registry included 470 participants (51% male). Genetic confirmation was obtained for 76% (n=356), the remainder were included based on clinical and anamnestic data. Clinical assessment forms and patient-reported questionnaires were analyzed for 310 and 142 patients, respectively. D4Z4 repeat unit (RU) distribution showed patterns consistent with European cohorts, with a predominance of patients with 3 RUs. A moderate inverse correlation was found between RUs number and clinical severity scales. Periscapular weakness was the most common onset manifestation (46.8%), followed by facial weakness (31.6%) which was often unnoticed by patients. The mean age in the Russian cohort was 37.8 years (range 0-97), indicating a younger cohort compared to international data. A delta-adjusted cluster analysis (n=215) identified three distinct trajectories: a classic phenotype with onset before age 14 and early involvement of various muscle groups (n=177), and two clusters characterized by either facial or periscapular onset with slow progression. ConclusionThe Russian FSHD registry provides a comprehensive characterization of a large national cohort, revealing a predominance of patients with 3 D4Z4 repeats and a younger demographic profile compared to international data. Cluster analysis identified three heterogeneous disease trajectories, offering a framework for improved patient stratification.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 2.05
- Field percentile
- top 10%
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hypomethylation of contracted D4Z4 repeats in facioscapulohumeral muscular dystrophy
Yosuke Hiramuki, Yuriko Kure, … Ichizo Nishino·medRxiv·Jun 24, 2022
- Single-molecule optical mapping enables quantitative measurement of D4Z4 repeats in facioscapulohumeral muscular dystrophy (FSHD)
Yi Dai, Pidong Li, … Kai Wang·Journal of Medical GeneticsPeer-reviewed·Sep 10, 2019
- A human pan-genomic analysis reconfigures the genetic and epigenetic make up of facioscapulohumeral muscular dystrophy
Valentina Salsi, Matteo Chiara, … Rossella Ginevra Tupler·medRxiv·Jun 13, 2023
- A circulating biomarker of facioscapulohumeral muscular dystrophy clinical severity, valid in skeletal muscle and blood
Christopher R. S. Banerji, Anna Greco, … Peter S. Zammit·bioRxiv·Aug 31, 2022
- The D4Z4caster DNA methylation signature identifies individuals at epigenetic risk for developing facioscapulohumeral muscular dystrophy (FSHD)
Takako I. Jones, Brooke Z Eriksen, … Oliver D. King·bioRxiv·May 29, 2026
- Validation of the association between MRI and gene signatures in facioscapulohumeral dystrophy muscle: implications for clinical trial design
Chao-Jen Wong, Seth D. Friedman, … Stephen J. Tapscott·bioRxiv·Feb 20, 2023